S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Buy THIS stock before Taiwan is attacked (Ad)
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
Buy THIS stock before Taiwan is attacked (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Buy THIS stock before Taiwan is attacked (Ad)
DOW New Hghs Coming Sooner Than Later
Will Advanced Micro Devices Follow NVIDIA Higher? 
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Buy THIS stock before Taiwan is attacked (Ad)
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
Buy THIS stock before Taiwan is attacked (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Buy THIS stock before Taiwan is attacked (Ad)
DOW New Hghs Coming Sooner Than Later
Will Advanced Micro Devices Follow NVIDIA Higher? 
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Buy THIS stock before Taiwan is attacked (Ad)
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
Buy THIS stock before Taiwan is attacked (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Buy THIS stock before Taiwan is attacked (Ad)
DOW New Hghs Coming Sooner Than Later
Will Advanced Micro Devices Follow NVIDIA Higher? 
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
Buy THIS stock before Taiwan is attacked (Ad)
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
Buy THIS stock before Taiwan is attacked (Ad)
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
Buy THIS stock before Taiwan is attacked (Ad)
DOW New Hghs Coming Sooner Than Later
Will Advanced Micro Devices Follow NVIDIA Higher? 
NASDAQ:NVNO

enVVeno Medical - NVNO Stock Forecast, Price & News

$5.01
+0.10 (+2.04%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.95
▼
$5.05
50-Day Range
$4.71
▼
$6.30
52-Week Range
$3.35
▼
$7.93
Volume
8,147 shs
Average Volume
18,859 shs
Market Capitalization
$47.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NVNO stock logo

About enVVeno Medical (NASDAQ:NVNO) Stock

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Receive NVNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter.

NVNO Stock News Headlines

March 22, 2023 | americanbankingnews.com
Contrasting enVVeno Medical (NASDAQ:NVNO) & Invo Bioscience (OTCMKTS:IVOB)
March 4, 2023 | finanznachrichten.de
enVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
March 22, 2023 | Upexi, Inc (Ad)
The Stock That Is Flying Under Wall St. Radar
With The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!pixel
March 2, 2023 | finance.yahoo.com
enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
February 8, 2023 | finance.yahoo.com
enVVeno Medical to Present at Cowen's 43rd Annual Health Care Conference
January 18, 2023 | finanznachrichten.de
enVVeno Medical Corporation: enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer
January 18, 2023 | finance.yahoo.com
enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer
January 11, 2023 | finance.yahoo.com
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
March 22, 2023 | Upexi, Inc (Ad)
The Stock That Is Flying Under Wall St. Radar
With The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!pixel
November 17, 2022 | finance.yahoo.com
Positive 3-Year VenoValve(R) First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues
November 7, 2022 | finance.yahoo.com
enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study
October 27, 2022 | finanznachrichten.de
enVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 27, 2022 | finance.yahoo.com
enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 14, 2022 | seekingalpha.com
NVNO enVVeno Medical Corporation
September 23, 2022 | seekingalpha.com
enVVeno Medical: Unique Exposure To Venous Treatment Domain
September 22, 2022 | finance.yahoo.com
enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference
September 21, 2022 | finance.yahoo.com
enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous Valve for the Treatment of Chronic Venous Insufficiency
September 19, 2022 | finance.yahoo.com
enVVeno Medical to Host Conference Call and Webcast on September 21, 2022
September 12, 2022 | finanznachrichten.de
enVVeno Medical Corporation: enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022 | finance.yahoo.com
enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022 | finance.yahoo.com
enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans
August 16, 2022 | finanznachrichten.de
enVVeno Medical Corporation: enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
August 16, 2022 | finance.yahoo.com
enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
August 14, 2022 | reuters.com
enVVeno Medical Corp
August 3, 2022 | finance.yahoo.com
enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update
July 8, 2022 | finance.yahoo.com
enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein
May 4, 2022 | finanznachrichten.de
enVVeno Medical Corporation: enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update
See More Headlines
Receive NVNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter.

NVNO Company Calendar

Last Earnings
8/11/2021
Today
3/22/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVNO
CUSIP
N/A
CIK
1661053
Web
www.hancockjaffe.com
Phone
(949) 261-2900
Fax
949-261-2992
Employees
19
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,670,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-55.04%
Return on Assets
-51.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
25.77
Quick Ratio
25.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.09 per share
Price / Book
1.22

Miscellaneous

Outstanding Shares
9,470,000
Free Float
7,928,000
Market Cap
$47.44 million
Optionable
Not Optionable
Beta
1.27

Key Executives

  • Robert Andrew BermanRobert Andrew Berman
    Chief Executive Officer & Director
  • Craig T. Glynn
    Chief Financial Officer & Treasurer
  • Marc H. GlickmanMarc H. Glickman
    Chief Medical Officer & Senior Vice President
  • Hamed Alavi
    Vice President-Research, Development & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NVNO Stock - Frequently Asked Questions

How have NVNO shares performed in 2023?

enVVeno Medical's stock was trading at $5.10 at the start of the year. Since then, NVNO stock has decreased by 1.8% and is now trading at $5.01.
View the best growth stocks for 2023 here.

When is enVVeno Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our NVNO earnings forecast.

How were enVVeno Medical's earnings last quarter?

enVVeno Medical Corporation (NASDAQ:NVNO) released its quarterly earnings results on Wednesday, August, 11th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06.

What is enVVeno Medical's stock symbol?

enVVeno Medical trades on the NASDAQ under the ticker symbol "NVNO."

Who are enVVeno Medical's major shareholders?

enVVeno Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Stanley (0.32%). Insiders that own company stock include Francis Duhay, Gmt Capital Corp, Holding SA Biodyne, Marc H Glickman, Matthew Jenusaitis, Robert Andrew Berman, Robert Gray and Sanjay Shrivastava.
View institutional ownership trends.

How do I buy shares of enVVeno Medical?

Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is enVVeno Medical's stock price today?

One share of NVNO stock can currently be purchased for approximately $5.01.

How much money does enVVeno Medical make?

enVVeno Medical (NASDAQ:NVNO) has a market capitalization of $47.44 million. The company earns $-24,670,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis.

How can I contact enVVeno Medical?

enVVeno Medical's mailing address is 70 DOPPLER, IRVINE CA, 92618. The official website for the company is www.hancockjaffe.com. The company can be reached via phone at (949) 261-2900 or via fax at 949-261-2992.

This page (NASDAQ:NVNO) was last updated on 3/22/2023 by MarketBeat.com Staff